N/A
Completed N=27
Erythrocyte and Adipocyte G6PD Activity Levels in Obesity
Source: ClinicalTrials.gov NCT01322035 ↗Enrolled (actual)
27
Serious AEs
0.0%
Results posted
May 2024
Primary outcomePrimary: Measure Erythrocyte G6PD Levels in Diabetic vs. Non-diabetic Morbidly Obese Patients Undergoing Laparoscopic Gastric Bypass. — 3.12; 0.67; 22; 13 nM/min/mg — p=<0.05
Summary
This study compares the improvement of weight, fasting lipid profile (triglycerides, cholesterol, HDL, and LDL) and diabetes after gastric bypass surgery with an improvement in levels of an enzyme called glucose-6-phosphate dehydrogenase (G6PD).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Measure Erythrocyte G6PD Levels in Diabetic vs. Non-diabetic Morbidly Obese Patients Undergoing Laparoscopic Gastric Bypass. |
3.12; 0.67; 22; 13; 20; 12 | <0.05 sig |
| SECONDARY Measure Adipocyte G6PD Levels in Diabetic vs. Non-diabetic Morbidly Obese Patients Undergoing Laparoscopic Gastric Bypass. |
3.12; 0.67; 22.1; 13; 21.9; 12.5 | — |
| SECONDARY Measure Omentum G6PD Levels in Diabetic vs. Non-diabetic Morbidly Obese Patients Undergoing Laparoscopic Gastric Bypass. |
13; 12 | — |
| SECONDARY Measure Hepatocyte G6PD Levels in Diabetic vs. Non-diabetic Morbidly Obese Patients Undergoing Laparoscopic Gastric Bypass. |
17; 11.9 | — |
Eligibility Criteria
Inclusion Criteria
- Age > 19 years of age and <70 years of age
- HGA1c<6.0%
- fasting blood sugar less than 100mg/dL
Exclusion Criteria
- Taking antidiabetic medications for other indications
Data sourced from ClinicalTrials.gov (NCT01322035). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.